• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Research of Patients and Physicians About Drug Delivery Technologies in the U.S. Produces Exciting New Study

Posted on: Tuesday, 4 March 2008, 09:01 CST

Recent patient and physician research conducted by Frost & Sullivan's Pharmaceutical/Biotechnology Group generates a new end user study on the preferences and drivers of adoption for various drug delivery technologies in the U.S. pharmaceutical market.

Through more than 200 detailed interviews with a variety of physician specialties such as Primary Care Physicians, Endocrinologists, Rheumatologists and Neurologists, as well as 450 patient interviews, research analysts identified key drivers and obstacles to adoption and utilization of various drug delivery technologies. Disease areas of focus for this research are diabetes, chronic pain, inflammatory diseases, and neurological disorders.

If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants an overview of this latest analysis of the U.S. Drug Delivery Markets, or sample slides of this study then send an e-mail to Melina Trevino - Corporate Communications at melina.trevino@frost.com with the following information: your full name, company name, title, telephone number, e-mail address, city, state, and country. We will send you the information via e-mail upon receipt of the above information.

"Understanding the views and desires of patients and physicians about drug delivery technologies is an important asset to drug developers," notes Frost & Sullivan Industry Manager, Daniel Ruppar. "As pharmaceutical and biotechnology companies seek to develop the medicines of the future, finding congruency with both patients and prescribers can make the difference between product success and failure. In the wake of the failure of the first inhaled insulin, this research reveals potential insight into areas of opportunity and high desire to end-users."

How important is ease of self-administration to patients? Understanding this question as well as points such as what is valued, willingness to try new technologies, and factors that may deter usage are key points of analysis that can aid companies throughout the drug development and marketing paradigm. In addition, this research analyzes patient responses for several specific products including Byetta, Exubera, Enbrel, Humira and Voltaren Gel, detailing factors such as awareness, usage, and desired product changes. Respondents also present feedback on usage and future adoption of auto-injectors.

"As companies seek product opportunities, an understanding of patient and physician views of drug delivery factors could influence portfolio and development decisions," explains Daniel Ruppar. "Additionally, understanding issues such as patient cost/copay and how value is important for developers."

"Manufacturers that can better understand the drivers and obstacles of adoption and utilization preferences for pharmaceutical drug delivery can develop and refine their technologies to best serve customer demand," says Ruppar. "The identification of technologies of high interest to clinicians and patients by disease area could lead to breakthrough products for developers."

The drug delivery market, valued at over $55.0 billion in 2006 is poised to undergo rapid expansion owing to major patent expiries, generic competition, increasing focus on life cycle management and tightening FDA regulations. Drug delivery technology companies enable drug companies to expand the product development options available to them. As a result, drug delivery companies expect to remain a focus point for developer companies including: pharmaceutical, biotechnology and specialty pharmaceutical companies.

U.S. Drug Delivery: Usage Patterns, Preferences and Opportunities in the U.S. is part of ongoing research conducted within the Pharmaceutical and Biotechnology subscription, which also includes research in the following markets: Contract Research and Manufacturing, Specialty Pharmaceuticals, Biopharmaceuticals, Vaccines, and Drug Delivery. Recent titles include: U.S. Biotechnology: Monoclonal Antibodies Market, Global CRO Spending Trends, and U.S. Specialty Pharmaceuticals -- Overview and Trends. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Analyst Interviews are available to the press.

Frost & Sullivan, the Global Growth Consulting Company, partners with clients to accelerate their growth. The company's Growth Partnership Services, Growth Consulting and Career Best Practices empower clients to create a growth focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents. For more information about Frost & Sullivan's Growth Partnerships, visit http://www.frost.com.

Source: Business Wire

More News in this Category